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Endocrine and Metabolic Aspects of OSA
Obstructive sleep apnea (OSA) is characterized by repeated spells of apnea. 
Collapsibility of hypopharynx due to multiple factors involving pharyngeal dilator 
muscles and deposition of fat or ﬂuid in the surrounding soft tissues are important 
contributing factors in its pathogenesis. OSA commonly affects obese individuals. 
Males are more commonly affected than the females probably due to the disturbing 
effect of testosterone on sleep. 
The impact of OSA on human health include disturbances in endocrine and metabolic 
system affecting hypothalamic-pituitary-gonadal axis, adrenocorticotrophic-cortisol 
axis, growth hormone, antidiuretic hormones and insulin resistance. There is a 
tendency for predisposition of the metabolic syndrome or its components including 
glycemic dysregulation, hypertension, hyperlipidemia and physical parameters related 
to adiposity. On the other hand, several endocrine disorders such as hypothyroidism, 
growth hormone excess, polycystic ovarian disease and testosterone replacement are 
associated with increased prevalence of OSA. 
There is limited information on the effect of treatment of OSA by continuous positive 
airway pressure (CPAP) on the endocrine and metabolic disturbances. There is a need 
to conduct randomized controlled trials using CPAP therapy in patients with OSA and 
to study its cause and effect relationship with endocrine and metabolic disturbances.          
Correspondence : Prof. Ravinder Goswami, Department of Endocrinology and 
Metabolism, All-India Institute of Medical Sciences, Ansari Nagar, New Delhi – 
110029. E-mail: gosravinder@hotmail.com
Ravinder Goswami
Department of Endocrinology and Metabolism
All-India Institute of Medical Sciences, New Delhi
ABSTRACT
Ann Natl Acad Med Sci (India), 49(3&4): 122-131, 2013
123Endocrine and Metabolic Aspects of OSA
OVERVIEW
Deposition of fat and ﬂuid in the 
soft tissues of the airways are important 
contributing factors in the pathogenesis of 
OSA (1,2). As expected, OSA is more 
common in obese individuals but can also 
be seen in non-obese subjects and children 
(3,4). Males are more commonly affected 
than the females probably due to 
disturbing effect of testosterone on sleep. 
With advancing age the protective effect 
of estrogen is lost leading to increased 
prevalence of OSA in postmenopausal 
women. OSA has been associated with 
increased incidences of diseases related to 
endocrine, nutritional and metabolic, 
nervous conditions, respiratory, skin and 
musculoskeletal system. 
T h e  p r o b l e m  o f  O S A a n d 
associated syndrome is also common in 
Indians with prevalence rate similar to that 
reported in the western population (5). 
Recent ly,  Sharma and Ahluwal ia 
summarized salient studies from India (5). 
The prevalence of OSA in North Indians 
and Western Indians was 9.3% and 19.5% 
respectively (5,6). The prevalence rates of 
OSA syndrome in these cohorts were 
2.8% and 7.5% respectively. The trend of 
higher prevalence in males than females 
was also observed in the Indian subjects. 
However, these studies cannot be taken as 
representative of the whole Indians in 
view of the wide variation in the 
s o c i o e c o n o m i c  d i f f e r e n c e s  a n d 
prevalence of obesity in Indians from 
different geographic regions.   
The purpose of the present review 
is to provide an overview of the endocrine 
manifestations covered in the Annual 
meeting of the National Academy of 
Medical Sciences held at AIIMS, Jodhpur 
in 2013. The endocrine implications of 
OSA have been covered recently in two 
excellent reviews by Attal and Chanson 
(1) and Kamenov et al. (2). The present 
review is based on relevant information on 
OSA summarized in these reviews and 
other published data. The search period 
was focused for studies available during 
2008 to 2013. Broadly, the information 
can be categorized as (A) effect of OSA on 
endocrine disturbances (B) effect of 
endocrine disorders on OSA and (C) 
disorders where the cause and effect 
relationship is not clear i.e. obesity, 
diabetes, insulin resistance and polycystic 
ovarian disease (PCOD).  
(A) Effect of OSA on endocrine 
disturbances 
Effect of OSA on hypothalamic-
pituitary-gonadal axis :
There is sexual dimorphism in the 
prevalence of OSA. This indicates the role 
of testosterone in sleep disturbance and 
protective effect of estradiol in females. 
Despite sexual dimorphism in the 
prevalence of OSA, alteration in sex 
hormone is a common feature in male and 
female patients with OSA. The low serum 
total testosterone level observed in OSA 
could be an effect of hypoxia on 
hypothalamic-pituitary-gonadal axis. 
Alternatively, it could be a confounding 
effect of obesity commonly associated 
with the OSA syndrome and related 
alteration in sex hormone binding 
globulin (SHBG). There is insufﬁcient 
data on sex hormone status (serum total 
and free testosterone) along with SHBG in 
subjects with OSA. Similarly, the effect of 
testosterone replacement and treatment 
with continuous positive airway pressure 
(CPAP) either alone or in combination has 
not been extensively studied using well-
designed placebo controlled randomized 
control trials (RCT). Recently, Hoyos et 
al., reported a RCT on the effect of 1000 
mg of testosterone undecanoate given for 
18 weeks in a group of 67 males. 
Testosterone supplemented group had 
th
worsening of O  desaturation index at 7  
2
week. The study concluded worsening of 
sleep disorder breathing in time dependent 
manner with testosterone in obese males 
with severe OSA (7). Meston et al., 
reported a RCT on the effect of nasal 
CPAP therapy in 101 male subjects with 
OSA. Testosterone and SHBG showed a 
negative correlation with the OSA 
severity at baseline. Active intervention 
group had a signiﬁcant elevation of SHBG 
and  r eve r s ib l e  change  in  se rum 
testosterone (8).
Changes in serum prolactin levels 
have also been documented in patients 
with OSA (9). The high serum prolactin 
level led to a negative effect  on 
hypothalamic-pituitary-gonadal axis in 
them. Recently, Macrea et al., reported the 
effect of CPAP therapy after 11 to 39 
months on serum prolactin, estradiol, 
FSH, LH, testosterone, glucose, cortisol 
and leptin (9). The CPAP therapy led to 
signiﬁcant fall in serum prolactin levels 
with no change in other hormones. The 
higher serum prolactin values observed 
seems to be a consequence of OSA and not 
a cause of OSA as patients with 
prolactinoma do not have increased 
prevalence of OSA syndrome (10). Thus, 
hypothalamic-pituitary gonadal axis is 
impaired in patients with OSA, but the 
causal role of obesity, SHBG and 
prolactin needs further evaluation. The 
effect of such disturbances on quality of 
life, infertility and sexual dysfunction is 
an important area requiring further 
studies.     
Effect of OSA on hypothalamic pituitary-
adrenal and thyroid Axis: 
Henley et al., assessed ultradian 
patterns of serum ACTH and cortisol 
using repetitive blood sampling in 10 
patients with moderate to severe OSA at 
baseline and at 3 months after CPAP 
therapy (11). The mean total ACTH and 
cortisol production were signiﬁcantly 
increased at baseline and the levels of both 
the hormones decreased after CPAP 
therapy. Pre-CPAP therapy, the subjects 
had signiﬁcantly elevated cortisol 
response to a single breath of 35% CO  
2. 
Lanfranco et al., observed increased 
ACTH response to CRH in patients with 
OSA, which was not explained by obesity 
(12). However, unlike the study by Henley 
et al., this study could not ﬁnd any 
signiﬁcant difference in the serum cortisol 
and ACTH levels in obese subjects with or 
without OSA. The increased serum 
cortisol level observed in OSA has also 
been implicated in the pathogenesis of 
metabolic syndrome associated with 
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OSA. However, the variable data obtained 
for the ACTH-cortisol axis in various 
studies, as exempliﬁed in the above two 
studies, indicates a need for further studies 
on this aspect. The thyroid axis has been 
found to be normal in most patients with 
OSA except for the pattern of sick 
euthyroid syndrome in severe OSA (2).
Effect of OSA on ﬂuid and electrolyte 
disturbances :
The increased effort of breathing 
in OSA creates a situation of excessive 
negative intra-thoracic pressure. This is 
analogous to increased volume load to the 
heart resulting in increased secretion of 
atrial natriuretic peptide from the heart. 
This peptide has inhibitory effect on      
the arginine vasopressin and renin 
angiotensin aldosterone system, which 
can result in increased glomerular 
ﬁltration. Thus, OSA favours suppression 
of vasopressin which could be the possible 
reason for the increased nocturia observed 
in some of the patients with OSA 
(2,13,14). Patients with OSA are also 
prone to resistant hypertension. Recently, 
Pimenta et al., evaluated 97 patients with 
resistant hypertension by overnight 
polysomnography and assessed 24-h 
urinary sodium and aldosterone excretion 
(15) .  28 .9% of  the  pa t ien ts  had 
hyperaldosteronism and 77.3% had OSA. 
Urinary sodium level was found to be an 
independent predictor of severity of OSA 
only in patients with hyperaldosteronism. 
The authors suggested restriction of 
dietary salt as a treatment strategy for 
management of  OSA in resis tant 
hypertension.
(B) Effect of endocrine disorders on 
OSA 
Growth hormone excess and OSA :
Acromegaly is associated with a 
remarkably high prevalence of OSA. 
Recently Roemmler et al., assessed the 
p r e v a l e n c e  o f  s l e e p  a p n e a  b y 
polysomnography in 52 patients with 
acromegaly (16). Twenty three of them 
had controlled disease activity with GH 
levels <1 μg/l and normal IGF-1 levels 
and 12 had active acromegaly despite use 
o f  s o m a t o s t a t i n  a n a l o g u e s .  T h e 
prevalence of OSA was 66% in patients 
with active disease and 48% in the cured 
group. Patients with acromegaly and OSA 
had higher mean HbA1c and  higher 
prevalence of hypertension than those 
without OSA. Though the OSA correlated 
with BMI, age and disease activity, it 
showed no signiﬁcant correlation with 
duration of the disease and serum growth 
hormone. Interestingly, ﬁve subjects had 
evidence of central sleep apnea either in 
isolated form or mixed with OSA. Thus, 
pat ients  with and without  act ive 
acromegaly are prone to OSA as well as 
central sleep apnea. The facial skeletal 
defects associated with acromegaly such 
as prognathism, widened angle of the jaw 
due to mandible position, thickened soft 
tissues of the nasopharynx including soft 
palate and uvula, with ﬂuid retention due 
to salt retaining effect of growth hormone 
are major factors responsible for increased 
prevalence of OSAS in the acromegaly. 
Besides, excess body weight and central 
hypothyroidism associated with pituitary 
mass lesion, hyperprolactinemia leading 
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to hypogonadism and changes in           
the neuromuscular structure of the 
pharyngeal  muscle  a lso possibly 
contribute in increased prevalence of OSA 
in acromegaly. Irreversibility of several of 
these changes especially skeletal structure 
might explain the persistence of the OSA 
syndrome after successful medical or 
surgical therapy (2).        
Paradoxically, adult patients with 
isolated growth hormone deﬁciency as 
e x e m p l i ﬁ e d  b y  p a t i e n t s  w i t h 
panhypopituitarism who were adequately 
replaced with all hormones except growth 
hormone also demonstrate increased 
prevalence of OSA. Replacement with 
growth hormone resulted in improvement 
in OSA in some of these patients but also 
had a worsening effect in others (2, 17).  
Hypothyroidism and OSA :
Increased sleepiness and weight 
gain are features common to both OSA 
and hypothyroidism. The prevalence of 
OSA has been found to be 25-35% in 
patients with hypothyroidism (2,18). 
Kapoor et al., studied 336 consecutive 
a d u l t  p a t i e n t s  u n d e r g o i n g 
polysomnography for suspected OSA and 
similar age and sex matched controls (18).  
The prevalence of hypothyroidism was 
only 1.4% in OSA. Moreover, all the 
s u b j e c t s  h a d  o n l y  s u b c l i n i c a l 
hypothyroidism indicating lack of case for 
routine screening for hypothyroidism in 
patients with OSA. Narrowing of the 
pharynx due to inﬁltration of the soft 
tissue by mucopolysaccharides might 
alter the control of the respiration (2). 
Presence of large goitre and macroglossia 
are the possible contributory factors      
fo r  the  pa thogenes i s  o f  OSA in 
h y p o t h y r o i d i s m  ( 1 9 ) .  M e d i c a l 
replacement therapy with L-thyroxin or 
surgery can reverse features of OSA 
syndrome specially when there is no 
obesity. Reiher et al has recently shown 
the important role of goitre in the 
pathogenesis of OSA (19) 71% of patients 
had Berlin questionnaire suggestive of 
OSA before thyroidectomy, which was 
decreased to 51% after surgery.  
Obesity, metabolic syndrome and OSA: 
Prevalence of obesity is high in 
patients with OSA. Peppard et al., showed 
that a 10% weight gain would result in 
32% increase in AHI (20). Similar 
relationship between obesity and OSA is 
observed in childhood obesity also (21). 
M o r a l e d a - C i b r i á n  a n d  O ' B r i e n 
investigated the association between short 
sleep duration, obesity and OSA in 306 
children undergoing polysomnography 
and observed prevalence of obesity, short 
sleep duration and OSA as high as 32 %, 
39.5 % and 78 % respectively (21).  
Children with OSA had a similar 
frequency of short sleep duration than 
those with no OSA. However, in children 
with short sleep duration, the odds ratio 
for obesity was 2.5 (95 % CI 1.3-4.9) 
compared to children with normal sleep 
duration even after accounting for the 
presence of OSA. The authors concluded 
that reduction in total sleep duration by 1 h 
was associated with a higher risk for 
obesity in children. Various aspects of 
obesity which could determine the 
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presence of OSA include (a) degree of fat 
deposition around upper airways and 
lateral wall of nasopharynx as reﬂected by 
neck  c i rcumference  (b )  r educed 
pulmonary volume consequent to 
abdominal  obesi ty and increased 
respiratory effort leading to decrease 
pulmonary traction of the upper airways 
and (c) impairment of the dilator muscle 
(2). Use of different criteria to deﬁne 
obesity such as BMI, waist or neck 
circumference and visceral fat in various 
studies could explain the variable 
prevalence of metabolic syndrome in 
OSA (2,3). Reduction of obesity by 
bariatric surgery can reverse or improve 
OSA (22). Greenberg et al., reported up to 
75% reduction in prevalence of OSA after 
bariatric surgery. However, there is a 
tendency of relapse for OSA after surgery. 
This could be related to that fact that 
despite successful surgery, some of the 
patients continue to have signiﬁcant fat 
deposition in the neck tissues (2, 22). 
Patient with OSA have high 
prevalence of metabolic syndrome with 
incidence as high as 60% (2,3). The 
prevalence of various components of 
metabolic syndrome such as dyslipidemia 
(hyper cholesterolemia in males and 
decreased HDL/increased triglycerides in 
females) waist to hip ratio, hypertension, 
insulin resistance and impaired fasting 
glucose have been found to be high in 
OSA. However, the independent link of 
metabolic syndrome with OSA after 
adjusting for obesity is not clear. 
Kamenov et al., reviewed various studies 
on the prevalence of metabolic syndrome 
in patient with OSA (2).  Several 
o b s e r v a t i o n a l  s t u d i e s  i n d i c a t e d 
association of OSA with metabolic 
syndrome or its individual components. 
Coughlin et al., carried out an RCT on the 
effect of CPAP on metabolic syndrome in 
34 subjects with OSA (23). Though 
arterial pressure decreased after 6 weeks 
of CPAP, there was no change in the 
insulin resistance or lipid proﬁle (23). 
Hoyos et al., recently studied 65 CPAP 
naïve adult men without diabetes who had 
moderate to severe OSA (24).  Subjects 
were randomized to receive either real or 
sham CPAP for 12 weeks. Though the AHI 
was lower on CPAP after 12 weeks, there 
were no between-group differences after 
12 weeks in the visceral fat, insulin 
sensitivity index and liver fat. The authors 
concluded that CPAP therapy in men with 
OSA would not lead to signiﬁcant 
reduction of visceral adiposity (24).
The pathogenesis of metabolic 
syndrome in OSA is not clear but could be 
related to pro-inﬂammatory cytokines and 
hormones produced from visceral fats 
including leptin, omentin, IL-6 and TNF-
alpha. Kurt et al., studied 46 patients with 
newly diagnosed OSA patients and 35 
normal subjects (25) and observed 
elevated circulating omentin in OSA.  
Both obesity and OSA can independently 
result in hyperleptinemia. Successful 
treatment of OSA by CPAP is predicted to 
decrease hyperleptinemia. Recently, 
Zirlik et al., studied 10 patients with  
newly diagnosed OSAS and healthy 
volunteers. Patients had signiﬁcantly 
higher plasma omentin-1 than healthy 
volunteers which decreased towards the 
values observed in the controls after three 
127Endocrine and Metabolic Aspects of OSA
months of CPAP therapy (26). 
The plasma melatonin peaked at 
2.00 a.m. in the healthy volunteers but at 
6.00 a.m. in patients with OSA. The 
abnormality in melatonin returned to 
normal after CPAP therapy. Whether these 
abnormalities associate with OSA 
independent of insulin resistance is not 
clear. Thus, there is a need to generate 
further data based on placebo controlled 
randomized trial with CPAP.     
Diabetes and OSA : 
Cross sectional and experimental 
studies suggest a link between OSA and 
increased prevalence of diabetes. 
However, the issue related to false 
association between OSA and DM exists 
in view of co-linear association between 
obesity and DM. Moreover, the methods 
used to rule out diabetes or to adjust 
obesity vary in different studies (2,3). 
These factors therefore do not allow ﬁrm 
association of diabetes with OSA. Tassone 
et al., studied insulin dynamics and 
glucose metabolism in 30 obese patients 
with OSAS and matched controls (27).  
The composite insulin sensitivity index 
values were signiﬁcantly lower in OSAS 
than in the obese and normal subjects. The 
authors concluded that obese patients with 
OSA syndrome had  higher insulin 
resistance than patients with simple 
obesity, independent of the degree and 
distribution of adiposity. Recently, 
Bozkurt et al., assessed 190 non-diabetic 
subjects grouped as controls, mild OSA, 
moderate OSA and severe OSA after 
polysomongraphy (28). Subjects with 
more severe OSA tended to have lower 
vitamin D levels which also correlated 
with increased prevalence of insulin 
resistance, pre-diabetes and diabetes 
status (28). Thus, vitamin D deﬁciency 
might also play a role in the OSA 
associated glycemic dysregulation. 
West et al., carried out a RCT in 
patients with OSA and DM and observed 
no signiﬁcant effect on the HbA1c values 
(29).  The pathogenesis of diabetes in 
OSA is similar to that of Type 2 DM with 
predominant effect on insulin sensitivity. 
Though data on insulin sensitivity in 
human is limited, there is strong support 
from animal studies on the pathogenetic 
mechanism of diabetes in OSA (30,31). 
Restriction of sleep in animal resulted in 
increased  preva lence  of  g lucose 
intolerance, hypertension and impaired 
pancreatic beta cell regenerative capacity 
especially in animal with hyperglycemia. 
Yokoe et al., developed a chronically 
catheterized, unhandled, lean adult male 
C57BL/J model to examine the effects of 
intermittent hypoxic exposure and 
exogenous glucose infusion on the diurnal 
pattern of blood glucose, and pancreatic 
beta-cell growth and function (31). 
Intermittent hypoxia impaired glucose 
homeostasis only during periods of 
h y p o x i c  e x p o s u r e .  P r e s e n c e  o f 
hyperglycemia increased the hypoxic 
suscept ib i l i ty  of  be ta -ce l l s .  The 
pathogenesis of increased prevalence of 
diabetes in OSA in human could also be 
related to increased serum cortisol, 
oxidative stress and its effect on lipid 
peroxidation, up-regulation of nuclear 
factor-kB (2,3).    
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Polycystic ovarian syndrome and OSA: 
  There has been increasing awareness 
about the association of PCOD with OSA 
(2,32,33). The prevalence of OSAS is 
increased by 10 fold in these patients (2). 
Vgontzas et al., observed 30 times higher 
risk of OSA among patients with PCOD 
compared to age matched controls (33) 
which was also associated with higher 
degree of insulin resistance, waist hip-ratio 
and glucose intolerance. The increased 
association between the two disorders is 
not clear but could represent a common 
pathogenesis such as insulin resistance or 
could be due to increase in serum 
testosterone in patients with PCOD and its 
destabilizing effect on sleep.  
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